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ABSTRACT: The antimalarial artemisinin (ART) possesses
anticancer activity, but its underlying mechanism remains
largely unclear. Using a chemical proteomics approach with
artemisinin-based activity probes, we identiﬁed over 300
speciﬁc ART targets. This reveals an anticancer mechanism
whereby ART promiscuously targets multiple critical biological
pathways and leads to cancer cell death. The speciﬁc
cytotoxicity of ART against colorectal cancer (CRC) cells
rather than normal colon epithelial cells is due to the elevated
capacity of heme synthesis in the cancer cells. Guided by this mechanism, the speciﬁc cytotoxicity of ART toward CRC cells can
be dramatically enhanced with the addition of aminolevulinic acid (ALA), a clinically used heme synthesis precursor, to increase
heme levels. Importantly, this novel ART/ALA combination therapy proves to be more eﬀective than an ART monotherapy in a
mouse xenograft CRC model. Thus, ART can be repurposed and potentiated by exploitation of its mechanism of action and the
metabolic features of the CRC cells.
■ INTRODUCTION
Artemisinin is an active compound of a Chinese herbal
medicine that has been used to treat chills and fever for at
least 2000 years.1 Currently, artemisinin and its derivatives
(herein collectively referred to as ART) are important frontline
drugs against uncomplicated malarial infections.2,3 Because of
their potency and rapid onset of action with few documented
adverse eﬀects, they are eﬀective in eliminating the otherwise
multidrug resistant parasite, Plasmodium falciparum.4 Beyond
these well-established antimalarial properties, there is accumu-
lating evidence demonstrating that artemisinin and its
derivatives possess cytotoxic eﬀects against many human cancer
cell types both in vitro and in animal experiments in vivo.5−10 As
an extension of these studies, our group in the United Kingdom
has recently conducted a randomized double-blind pilot clinical
phase II trial using oral artesunate (the salt form of artesunic
acid, a derivative of artemisinin) neoadjuvant therapy in
colorectal cancer (CRC) patients. It was shown that artesunate
is generally well tolerated and has antiproliferative properties in
CRC patients.11 These preliminary data suggest artesunate as a
promising drug in CRC treatment regimens, and a more
thorough study is being conducted with a larger patient sample.
Yet, the detailed anticancer mechanism of action (MOA) of
ART has not been fully understood.12 Artemisinin and its
derivatives such as artesunate are prodrugs which require
cellular activation to cleave the endoperoxide moiety for
antimalarial and anticancer eﬃcacy.13−17 However, the identity
of the activator remains inconclusive. On one hand, previous
studies have proposed the role of iron18−24 in the in vitro decay
of ART endoperoxide. On the other hand, other studies have
pointed out a similar function for heme depending on the
context of the cellular environment.13−17,25−27 Recently, using
chemical proteomics approaches, we28−31 and other
groups32−34 have independently shown that ART can be
activated by heme before indiscriminately alkylating multiple
proteins. However, given the biological diﬀerences between
cancer cells and malaria parasites, the postactivation or
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downstream mechanisms by which ART exerts its cytotoxicity
are likely to diﬀer from its antimalaria mechanism.12,28−35 Here,
we sought to understand the following in the speciﬁc context of
cancer cells: (i) What are the detailed pathways aﬀected by
ART treatment and the mechanisms explaining its anticancer
eﬀects? (ii) How can ART speciﬁcally kill cancer cells but not
normal cells? (iii) Is it possible to further enhance the
anticancer eﬀect of ART, given that ART derivatives have been
selected for antimalarial potency but not anticancer eﬃcacy?
To address these questions, we ﬁrst used alkyne (AP1)- and
biotin (AP2)-tagged ART probes (Figure 1) to speciﬁcally
identify protein targets and their implicated biological pathways
in CRC cells. Several pathways that were disrupted by ART
treatment were examined in detail. Importantly, we found that
the speciﬁcity of ART against CRC cells could stem from the
elevated capacity of heme synthesis in the cancer cells versus
the normal cells. Based on this distinctive metabolic feature of
CRC cells, we introduced a clinically used heme synthesis
precursor, aminolevulinic acid (ALA), as a sensitizer of
artesunate to speciﬁcally increase the heme level and thus
dramatically enhance its anticancer eﬀects. The eﬃcacy of this
newly developed ART/ALA combination therapy was further
validated in a mouse xenograft CRC model (Figure 1).
■ RESULTS AND DISCUSSION
To characterize the direct binding targets of ART and its MOA
in CRC cells, an alkyne-tagged artemisinin-based probe AP1
was used to enrich and visualize its interacting protein proﬁle
on an SDS−PAGE gel.28,29 To further increase the stringency
of protein target identiﬁcation, we also synthesized a biotin-
tagged ART probe AP2 (Scheme 1). Only the targets that were
consistently identiﬁed with both probes were considered as
speciﬁc ART targets in CRC cells. The in vitro growth
inhibitory assay conﬁrmed that both probes largely retained the
anti-CRC eﬀects as shown in Figure S1, indicating that our
tagging strategies do not interfere with drug activation or
targeting (Figure 1).
The protein binding targets of ART in CRC cells were
labeled with AP1 and visualized by conjugating AP1 with a
ﬂuorescence dye through click chemistry. Live CRC cells
treated with increasing concentrations of AP1 showed
increasing levels of drug target labeling upon in-gel ﬂuorescent
scanning (Figure 2b). The direct targets of ART were enriched
by streptavidin aﬃnity puriﬁcation and identiﬁed with mass
spectrometry. Nonspeciﬁcally bound proteins were ﬁltered out
by comparing the enrichment ratio of the pull-down group
versus the control group, with a stringent enrichment ratio of 2
as the cutoﬀ (with a minimum of two quantiﬁed peptides). In
total, 304 proteins were consistently identiﬁed by both probes
as speciﬁc targets of ART (the full list is shown in Table S1).
Seven representative proteins from the target list were selected,
and their interactions with AP1 were further veriﬁed by
immunoblotting (Figures 2a and 2c).
Gene ontology (GO) analysis revealed that ART’s cellular
targets are widely distributed in diﬀerent subcellular compart-
ments (Figure 3a). To visualize the cellular localization of ART
binding targets, we employed a ﬂuorescence (TAMRA)-tagged
ART probe. Probe-treated CRC cells showed high level of
ﬂuorescent signal evenly distributed throughout the cells,
consistent with the GO analysis. No ﬂuorescence could be
observed in the DMSO-treated control cells (Figure 3b).
Ingenuity pathway analysis (IPA) further suggested that ART
may exert its cytotoxicity on cancer cells by targeting multiple
critical functions and pathways including the EIF2, mitochon-
drial functions, phagosome maturation, and eIF4/p70S6K
pathways (Figure 3c), with possible inﬂuences on the fatty
acid metabolism, protein synthesis, autophagy, and free radical
scavenging process (Figure 3d). Based on these predictions, we
next carried out validation studies on possible functional
pathways aﬀected by ART treatment.
First, we examined the changes in the levels of protein
synthesis (Figures 4a, 3d, and S2) in HCT116 cells upon
artesunate treatment using the artiﬁcial amino acid azidoho-
moalanine (AHA), a methionine analogue that is incorporated
into proteins that are newly synthesized and allows the dynamic
monitoring of de novo protein synthesis.36,37 Newly synthesized
proteins with AHAs incorporated were subsequently con-
jugated with a ﬂuorescence tag through a click chemistry
reaction, and ﬂow cytometry was used to measure the
ﬂuorescence intensity of the labeled cells to quantify the
relative level of newly synthesized proteins. It was shown that
artesunate inhibited the de novo protein synthesis in a dose
dependent manner, and 2 μM artesunate treatment for 12 h led
to a 50% reduction of the protein synthesis in HCT116 cells
(Figure 4a).
In cancer pathogenesis, endogenous fatty acid biosynthesis is
substantially upregulated to provide essential building blocks
for phospholipid membranes, conferring growth advantages to
cancer cells.38 Our chemical proteomics data and pathway
analysis identiﬁed fatty acid synthase (FASN) as well as various
other mediators of lipid metabolism as ART binding targets
Figure 1. An outline of the quantitative chemical proteomics study of
the molecular mechanism for ART’s speciﬁc anticancer property and
its combination with aminolevulinic acid (ALA).
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(Figures 2a and S3). FASN inhibition has been investigated as a
potential therapeutic avenue for speciﬁc cancers.38−40 To
investigate ART’s eﬀect on FASN, palmitatethe end product
of FASN’s catalytic reactionwas used to treat HCT116 cells
with or without the presence of artesunate. As shown in Figure
4b, the antiproliferative eﬀect of artesunate was partially
rescued by palmitate addition. This suggests that artesunate
may inhibit fatty acid synthesis through binding with FASN and
other targets (Figures S3), partially contributing to its
anticancer eﬀect.
Autophagy is a catabolic process that results in degradation
of bulk cytoplasmic contents, abnormal protein aggregates, and
excess or damaged organelles through autophagosome−
lysosome fusion,41 which is negatively regulated by the kinase
mTOR. mTOR activation by Akt or MAPK signaling inhibits
autophagy whereas mTOR inhibition by AMPK or p53
signaling enhances autophagy.42 As reﬂected in our pathway
analysis, EIF2, phagosome maturation, and eIF4/p70S6K
pathways were involved in ART-treated cells. These pathways
are highly related to the autophagy process. Here, we examined
the eﬀect of ART on autophagy. As shown in Figure 4c, in the
presence of chloroquine, a lysosomal inhibitor,43 artesunate
signiﬁcantly enhanced the levels of autophagic marker LC3-II
and reduced levels of autophagy substrate p62, indicating that
artesunate causes cellular damage and increases autophagic ﬂux
in HCT116 cells. Consistent with this, confocal microscopy
showed that artesunate also increased the abundance of GFP-
LC3 puncta in Hela cells (Figure 4d). Moreover, lysoTracker
staining in HCT116 cells showed that artesunate signiﬁcantly
enhanced lysosomal activation (Figure 4e), which further
Scheme 1. Structure and Synthetic Scheme of Alkyne-Tagged Artemisinin Probe AP1 and Biotin-Tagged Artemisinin Probe
AP2a
aOf note, AP1 has been published in our previous report.28
Figure 2. (a) Selective targets of ART in HCT116 cells. (b) In situ ﬂuorescence labeling of HCT 116 cells to show the cellular targets of ART. (c)
Western blot validation of pulled-down fractions of HCT116 by AP1 (or DMSO as negative control) with respective antibodies.
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promotes the autophagosomal degradation during later stages
of autophagy.
Our pathway analysis also suggested mitochondrial dysfunc-
tion upon ART treatment, which might lead to elevated reactive
oxygen species (ROS) production. We found that artesunate
signiﬁcantly increased ROS levels (Figure 4f) in HCT116 cells
while cotreatment with ROS scavengers could partially rescue
the cell death induced by artesunate (Figure S4). The increase
of ROS not only directly contributes to cancer cell death but
also leads to autophagosome formation and autolysosomal
Figure 3. (a) Cellular components of the ART targets determined by GO analysis. (b) Images of HCT116 cells treated with red ﬂuorescent ART.
Cells were treated with TAMRA-tagged ART probe (20 μM) for 30 min and were subjected to analysis by confocal microscopy. (c) Top canonical
pathways with the ART protein targets signiﬁcantly over-represented. (d) Top cellular and molecular functions that are associated with ART-
targeted proteins.
Figure 4. (a) Dose-dependent reduction of protein synthesis by artesunate (Arts) (0.5 μM, 1 μM, 2 μM, 12 h) in HCT116 cells. Data shown are
mean ± SD from triplicate experiments (*p < 0.05, **p < 0.01, Student’s t-test). (b) Cell viability of HCT116 cells treated with Arts (2 μM) for 24 h
with or without the presence of palmitate. (c) Arts increases autophagic ﬂux in HCT116 cells. HCT116 cells were treated with Arts (5 μM) for 12 h
with or without chloroquine (CQ; 25 μM), and cell lysates were prepared for Western blot. (d) HeLa cells stably expressing GFP-LC3 were treated
with Arts (5 μM) for 12 h. GFP-LC3 puncta were observed under confocal microscopy. (e) ART activates lysosomal function in HCT116 cells.
HCT116 cells were treated with Arts (5 μM) for 12 h and then stained with LysoTracker Red DND-99 (50 nM) for 15 min. Confocal microscopy
was performed to analyze. (f) ROS level increases in HCT116 cells upon Arts treatment. Cells were treated with 5 μM Arts for 12 h, followed by
DCFH-DA staining and ﬂow cytometry analysis.
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degradation, which further overwhelms the cellular sys-
tem.6,35,44
After detailed dissection of the functional pathways for ART’s
anticancer eﬀects, we next attempted to uncover the molecular
mechanism of the speciﬁcity of ART against cancer cells versus
normal cells. Previous research by us and other groups have
shown that artesunate is activated by heme to generate reactive
free radicals that can promiscuously alkylate various cellular
targets.14,28−34 Heme, as an essential cofactor of many
important cellular enzymes, is involved in several critical steps
of cell metabolism.45,46 We hypothesize that cancer cells, with
higher metabolic rate for rapid growth, may also require higher
levels of heme synthesis. Thus, ART activation could be
speciﬁcally enhanced in this context. The heme levels of
HCT116 (colon cancer cell line) and CCD841 (normal colon
epithelial cell line) were ﬁrst measured and compared.
Consistent with our hypothesis, the cancerous HCT116 cells
have higher heme level than the noncancerous CCD841 cells
(Figure 5a). In mammalian cells, heme is synthesized in both
the mitochondria and cytosol by a series of metabolic reactions
(Figure 5b).45 The rate-limiting step of the heme synthesis
pathway is the production of aminolevulinic acid (ALA),
catalyzed by ALA synthase (ALAS1).47 We therefore examined
the expression level of this key enzyme by immunoblotting.
Our results demonstrated that the ALAS1 level in HCT116
cells was substantially higher than that of CCD841 cells (Figure
5c and 5d), suggesting an enhanced capacity of heme synthesis
in cancer cells to sustain faster growth. Notably, we found that
the amount of ALAS1 was signiﬁcantly higher in HCT116 cells
when treated with artesunate, while minimal change was found
in the normal cells (Figures 5c and 5d). Consistent with
enhanced heme synthesis in HCT116 cells, a substantially
higher level of ART activation and targeting was observed by
in-gel ﬂuorescence scanning (Figure 5e). Importantly, this
correlated well with the viability of HCT116 cells and CCD
841 cells upon ART treatment (Figures 5f and 5g). The
elevated heme level in cancer cells thus corresponds to the
enhanced activation of ART and its subsequent multipathway
targeting, and eventually cell death. In contrast, heme levels in
normal cells and tissues are strictly controlled and maintained
at lower levels, minimizing ART’s activation, which could
possibly explain the speciﬁcity and low toxicity of ART.46
However, we cannot rule out the potential contribution
of the intracellular iron inside cancer cells to ART activation,
the broad targeting spectrum, and its downstream
events.20−22,24,48,49
Although ART has shown some promising anticancer eﬀects,
its potency is somewhat limited compared to its remarkable
antimalarial eﬀects and the IC50 of ART against cancer is in the
micromolar range.5 Artesunate is transformed to dihydroarte-
misinin (DHA), and DHA has a relatively short elimination
half-life (∼45m) with Cmax values in the low micromolar range
when used in antimalarial therapies.50 The high potency of
artesunate in antimalarial parasite therapy (with IC50 values in
the low nanomolar range) is due to rapid drug activation
triggered by high concentration of heme released by
hemoglobin digestion.14 Thus, the antimalarial eﬀect is not
compromised given the limited drug exposure time.51 Although
ART can be similarly activated by heme in cancer cells, the
heme level is much lower compared to the case of malaria
parasites which undergo massive hemoglobin digestion.3
Previously, we have developed a mitochondrial targeting ART
analogue that can target ART to the sites of heme synthesis in
mammalian cells.29 In this manner, ART activation can be
Figure 5. (a) Assessment of heme levels in normal (CCD841) and colorectal cancer cells (HCT116) in the absence (basal) and presence of 1 mM
ALA treatment for 24 h. (b) Schematic diagram of the eﬀects of exogenous modulators on the heme biosynthetic pathway. (c) The protein levels of
heme biosynthetic enzyme ALAS1 in CCD841 and HCT116 in the absence (basal) and presence of artesunate (Arts) treatment. (d) Normalized
protein expression levels of ALAS1 for the results from panel c. Tubulin level was used for normalization. (e) The ﬂuorescence labeling (4 h) of
HCT116 and CCD841 cells with and without (basal) 1 mM ALA treatment. (f) Eﬀects of Arts and ALA combination treatment on HCT116 cell
viability. (g) Eﬀects of Arts and ALA combination treatment on CCD 841 cell viability. Error bars represent SD of triplicate experiments in panels a,
d, f, and g.
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enhanced by directly delivering the drug to heme-concentrated
regions of the cell. Thus, we hypothesized that another possible
strategy to enhance ART’s anticancer eﬀect is to increase the
level of intracellular heme, thereby enhancing ART activation
and its cytotoxicity. As mentioned above, we have found that
the ALA synthase enzyme was highly expressed in cancer cells
in comparison with normal cells, implying a higher capacity of
cancer cells to utilize ALA for heme synthesis. ALA itself is a
clinically used drug in photodynamic therapy for imaging-
guided surgery or tumor treatment.52 It has been reported to
have minimal side eﬀects and is clinically safe for cancer
treatment.52−54 Therefore, we introduced ALA as a potential
sensitizer to enhance the eﬃcacy of artesunate by increasing
heme levels to enhance artesunate activation. We examined
cancer cell viability after treatments with artesunate, artesunate
+ ALA, and artesunate + ALA + SA (succinylacetone, an
inhibitor of heme synthesis) respectively. As shown in Figure
5f, artesunate treatment alone for 24 h had an IC50 of
approximately 2 μM, while the addition of ALA lowered the
IC50 approximately 10-fold to around 200 nM. The addition of
the heme synthesis inhibitor SA fully blocked the cytotoxicity of
artesunate treatments, regardless of the presence of ALA,
strongly supporting a heme-centric mechanism for both single
and combination treatments. In normal cells, no signiﬁcant
killing is observed in either ART or ART + ALA treatment even
when the concentration of ART was as high as 20 μM (Figure
5g). Consistently, addition of ALA indeed increased intra-
cellular heme level and enhanced ART activation in cancer cells
but had negligible eﬀect in normal cells (Figures 5a and 5e).
This may explain the speciﬁc enhancement of the anticancer
eﬀects of the ART + ALA cotreatment.
Finally, to determine whether the eﬃcacy of artesunate and
ALA combined treatment against CRC cells (HCT116)
observed in vitro can be recapitulated in vivo in mouse
xenograft models, the following treatments were administered
to male nude mice inoculated with visible tumors: (1) control
(PBS), (2) ALA, (3) artesunate, and (4) artesunate + ALA for
8 days. Consistent with previous reports, artesunate admin-
istration exhibited inhibitory eﬀects against tumor growth
(Figures 6a and 6b; Figures S5a and S5b).55,56 Strikingly, the
combination of artesunate and ALA showed signiﬁcant tumor
growth delay in comparison to both the control and the
artesunate or ALA single treatment groups, supporting the
notion that ALA can potentiate the anticancer eﬀects of
artesunate. Interestingly, ALA treatment also inhibited tumor
growth to some extent, which might be related to its potential
photodynamic eﬃcacy on tumors.52−54 As a control, the
tolerance of the combined treatment of artesunate and ALA
was conﬁrmed by the comparable body weight reduction
among diﬀerent groups (Figure S5c). Consistently, the ART
activation level in the mouse tumor tissue was shown to be
elevated by the combination treatment, as revealed by in-gel
ﬂuorescence scan (Figure 6c).
■ CONCLUSIONS
In conclusion, we have comprehensively characterized the
targets and biological pathways disrupted by ART in the
context of colorectal cancer. We propose a heme-centric
mechanism to explain ART activation and speciﬁcity in cancers.
Based on this heme-centric activation model, we further
designed a novel ART combination therapy by incorporation
of a heme precursor ALA as a potent enhancer of ART’s
anticancer eﬀects, and demonstrated the eﬃcacy of this
combination in both cancer cell lines and animal models.
Since both artesunate and ALA are clinically used and well-
tolerated,52 this combination has the potential to be safely
applied to subsequent clinical testing, pending further study
into its pharmacokinetics and pharmacodynamics proﬁles. As
the level of free ferrous iron is relatively high in cancer cells and
it can catalyze the breakage of the endoperoxide bridge of
ART,18−24 its contribution both to ART activation and to
downstream events in cell lines and animal models should be
further investigated. Iron-based strategies, such as the well-
reported coadministration of ART with holotransferrin,57,58
might also turn out to be an interesting avenue of exploration in
conjunction with the presently described heme-based combi-
nation. Finally, alternative formulations such as several
artemisinin-derived dimers7−10,22,59,60 with higher anticancer
potency have been developed recently, and these promising
artemisinin derivatives can also be tested as combination
therapy in the future.
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Figure 6. (a, b) In vivo eﬃcacy comparison of artesunate (Arts), ALA, and combined treatment in human colon cancer xenograft models. Five days
after subcutaneous implantation of 3 × 106 HCT116 cells in PBS, male nude mice received one dose of the following treatments: (1) Ctrl (PBS), (2)
ALA (100 mg/kg), (3) Arts (50 mg/kg), or (4) Arts (50 mg/kg) plus ALA (100 mg/kg) via intraperitoneal (ip) injection every day. After 8 days of
administration, tumors were isolated, and tumor volumes were examined and estimated every day. Each data point represents mean tumor volume of
at least 7 tumors in each group ± SE. p value, *<0.05; **<0.01. (c) The mice were treated for 4 h with AP1 probe or other treatments, and the
tumors were harvested and lysed for in-gel ﬂuorescence scanning.
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